Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

Fig. 5

The change in eGFR overtime in initiators of GLP-1 RAs versus basal insulin in the ITT and AT analyses, by baseline subgroups. We calculated an eGFR slope per patient by fitting a linear regression model. We then calculated the mean eGFR slope over time for each group and used t-test to compare the treatment groups. eGFR slopes are presented as mL/min/1.73 m2/year. BDL below detectable levels, BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, GLP-1 RAs glucagon-like peptide 1 receptor agonist, HbA1c glycated hemoglobin A1c, RAAS renin angiotensin aldosterone system, SGLT2i sodium-glucose transporter 2 inhibitors, UACR urine albumin-to-creatinine ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840